hotspot -WSS

hotspot

author：fashion 2025-10-06 07:43:46 - browse：18

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： What we know about the American soldier detained in North Korea

WSS

FDA panel to weigh safety of artificial wombs for preterm births

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Transgender sports debate: Physicians say bans are health issue

FDA panel to weigh safety of artificial wombs for preterm births

hotspot

hotspot

The next ALS data readout — overdue but important

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

FDA panel to weigh safety of artificial wombs for preterm births

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

BioMarin wins approval for gene therapy to treat hemophilia A

FDA seeking to stop procedures at two unregulated stem cell clinics

How to save PrEP access — and even expand it

House panel takes first step toward fixing drug shortages

New air purifier tech could be key to improving indoor air quality

The struggle to figure out which patients 'deserve' Wegovy

focus

Information blocking fines are now fair game in health care

Eli Lilly CEO gives to Mike Pence presidential super PAC

FDA weighs limits of animal data in assessing artificial wombs

Senate bill would ban some hospital facility fees

Biden administration sends mixed signals on US soldier who crossed into North Korea

More hospitals are billing patients as online messages surge

entertainment

hotspot

focus

entertainment